Copley releases a new version of Inhalytix®, the go-to software for inhaler testing analysis

30 July 2024; Nottingham, UK: The latest version of Inhalytix®, the innovative software solution from Copley, makes it quicker and easier to transform raw analytical data into the performance-defining metrics needed for evaluating orally inhaled and nasal drug product (OINDP) performance. New features, such as the ability to analyse multiple active pharmaceutical ingredients (APIs) in a single test, address the complexities of modern inhaler formulations and reinforce Inhalytix as the go-to solution for end-to-end Aerodynamic Particle Size Distribution (APSD) data management. Trusted by laboratories across the world, this powerful software is also now easier than ever to use.

“Copley’s goal of providing complete solutions for OINDP testing naturally extends to user-friendly software for the critical task of data processing,” said Matthew Fenn, Head of Business Development. “Inhalytix takes the raw data from cascade impaction analyses and converts it into the APSD metrics that analysts need, to understand and improve OINDP performance and confirm product quality. The latest update reflects our commitment to continuous improvement, guided by customer feedback, and represents a significant step forward in the ongoing evolution of Inhalytix.”

Regulatory requirements call for the measurement of APSD by cascade impaction for all OINDPs. These analyses produce substantial quantities of data which need to be processed to determine critical metrics. Building on the success of previous versions, the latest Inhalytix update adds the ability to analyse up to 6 APIs in a single test, to handle multi-active products with ease. There is also now the option to input shot weight data (mean and standard deviation) directly to ensure accuracy and enhance precision.

Improved usability and data handling are also evident in the latest release, resulting in a better user experience, improved data integrity and easier compliance, notably with 21 CFR Part 11 regulations. Expanded reporting functionality makes it easier for all users to customise data presentation to support effective communication and empower decision-making.

Find out more about the latest version of Inhalytix and how it could improve your inhaler testing performance by visiting here or contacting Copley Scientific at Tel: +44 (0)115 961 6229 or sales@copleyscientific.co.uk.